All In Biotech

Drug Trial Radar · NCT07569965

Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

Phase II Multicenter Trial of MB-CART2019.1 (Zamtocabtagene Autoleucel) Therapy as Frontline Consolidation for High-Risk Mantle Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2029

Study completion Mar 2030

Sponsor

Lead sponsor
Miltenyi Biomedicine GmbHIndustry
Sponsor type
Industry
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FRONTIER is a prospective, single arm, open label, multi-center, Phase II study of MB-CART2019.1 (Zamtocabtagene Autoleucel) therapy as frontline consolidation for high-risk Mantle Cell Lymphoma (MCL) participants

Conditions

  • Mantle Cell Lymphoma (MCL)

Interventions

  • zamtocabtagene autoleucel (MB-CART2019.1)Biological

    chimeric antigen receptor T-cell (CAR-T) therapy

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy

  • FludarabineDrug

    Lymphodepleting chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: 1 year post-infusion

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.